As customer demand rises, WuXi to increase Worcester manufacturing capacity 50%
Photo | Courtesy of WuXi Biologics
Jie Chen, senior vice president and head of MFG11 and MFG18 sites for WuXi Biologics.
WuXi Biologics, a Chinese science company constructing a 189,500-square-foot facility at The Reactory biomanufacturing campus on Belmont Street in Worcester, plans to increase its manufacturing capacity in the city by 50%.
The firm will increase its local total manufacturing capacity from 24,000 liters of commercial drug substance to 36,000 liters in response to increasing demand from global clients, according to a press release issued by the company on Monday.
“The new commercial capacity in Worcester represents a key part of our global biomanufacturing network, reflecting our commitment to continuously strengthen our capabilities in line with anticipated market and client needs,” Chris Chen, CEO of Wuxi Biologics, said in the release. “We look forward to providing more efficient and cost-effective manufacturing processes and enabling our clients to bring new biologics to patients.”
This news comes after a 2022 announcement where the company said it had quintupled its investment into the new Worcester facility to $300 million. The new facility has achieved weather tight status and is expected to begin operations in 2025, according to this Monday’s release.
WuXi Biologics has 400+ employees in the United States, and the new Worcester facility is expected to create an additional 200 jobs when it is fully online. A total of 250 employees are planned to work in The Reactory facility.
WBJ Web Partners
Most Recent
Most Recent
0 Comments